HC Wainwright & Co. initiated coverage on Kronos Bio with a new price target
$KRON
Biotechnology: Pharmaceutical Preparations
Health Care
HC Wainwright & Co. initiated coverage of Kronos Bio with a rating of Buy and set a new price target of $35.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/14/2024 | $6.00 → $1.00 | Overweight → Neutral | Piper Sandler |
| 11/14/2024 | Buy → Hold | TD Cowen | |
| 9/14/2022 | $12.00 | Buy | Berenberg |
| 2/28/2022 | $50.00 → $30.00 | Overweight | Piper Sandler |
| 11/10/2021 | $35.00 → $36.00 | Buy | HC Wainwright & Co. |
| 10/20/2021 | Outperform | Cowen | |
| 6/24/2021 | $35.00 | Buy | HC Wainwright & Co. |
4 - Kronos Bio, Inc. (0001741830) (Issuer)
4 - Kronos Bio, Inc. (0001741830) (Issuer)
4 - Kronos Bio, Inc. (0001741830) (Issuer)
– Preclinical data demonstrate the ability of p300 KAT inhibition to modulate multiple pro-inflammatory signaling pathways, including antibodies and cytokine production, in ex vivo and in vivo models at well tolerated exposures – SAN MATEO, Calif. and CAMBRIDGE, Mass., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (NASDAQ:KRON), a company developing small molecule therapeutics that address cancers and other diseases driven by deregulated transcription, today highlighted preclinical data from its p300 KAT inhibitor program for autoimmune indications at the American College of Rheumatology's annual meeting, ACR Convergence 2024. The oral presentation will take place on Monday, November
– Discontinuing development of istisociclib, a CDK9 inhibitor; benefit-risk profile in platinum-resistant high-grade serous ovarian cancer does not support further development – – Kronos Bio Board of Directors has approved plan to evaluate strategic alternatives to maximize stockholder value – – Kronos Bio's additional pipeline assets include preclinical p300 KAT inhibitor programs in oncology and autoimmune disease – — $124.9 million cash, cash equivalents, and investments as of September 30, 2024 — SAN MATEO, Calif. and CAMBRIDGE, Mass., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (NASDAQ:KRON), a company developing small molecule therapeutics that address cancers and autoimm
– Data demonstrates Kronos Bio's approach to targeting oncogenic transcription factors and the strong relationship between IRF4 and p300 in Multiple Myeloma – – Poster presentation to take place on Monday, December 9, 2024 – SAN MATEO, Calif. and CAMBRIDGE, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (NASDAQ:KRON), a company dedicated to developing small molecule therapeutics that address cancers and autoimmune diseases driven by deregulated transcription, today announced that it will present preclinical data from its p300 KAT inhibitor program for multiple myeloma at the American Society of Hematology (ASH) Annual Meeting taking place in San Diego, California from December
EFFECT - Kronos Bio, Inc. (0001741830) (Filer)
10-Q - Kronos Bio, Inc. (0001741830) (Filer)
8-K - Kronos Bio, Inc. (0001741830) (Filer)
Piper Sandler downgraded Kronos from Overweight to Neutral and set a new price target of $1.00 from $6.00 previously
TD Cowen downgraded Kronos from Buy to Hold
Berenberg initiated coverage of Kronos with a rating of Buy and set a new price target of $12.00
SC 13G/A - Kronos Bio, Inc. (0001741830) (Subject)
SC 13D/A - Kronos Bio, Inc. (0001741830) (Subject)
SC 13D/A - Kronos Bio, Inc. (0001741830) (Subject)
4 - Kronos Bio, Inc. (0001741830) (Issuer)
4 - Kronos Bio, Inc. (0001741830) (Issuer)
4 - Kronos Bio, Inc. (0001741830) (Issuer)
Demonstrated on-mechanism, single agent anti-tumor activity in heavily pre-treated patients with transcriptionally addicted solid tumors Showed manageable safety profile, with no grade 3/4 neutropenia, dose proportional exposure, dose-dependent target engagement, and 24-hour plasma half-life Dose escalation continues; dosing of patients at the 80 mg dose level is ongoing Enrollment ongoing in dose expansion phase in MYC-dependent and other transcriptionally addicted solid tumors, including lung, ovarian, and triple negative breast cancers Company to host conference call and webcast today at 4:30 PM ET with key opinion leader and KB-0742 trial investigator, Miguel Villalona-Calero, M.D.
SAN MATEO, Calif., and CAMBRIDGE, Mass., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (NASDAQ:KRON), a company dedicated to transforming the lives of those affected by cancer, today announced that it will host a conference call and webcast on Friday, October 13, 2023, at 4:30 p.m. ET., followed by a Q&A session. The event will feature trial investigator, Miguel Villalona-Calero, M.D, Medical Oncologist and Director of Early Therapeutics, City of Hope, along with Kronos Bio management, who will discuss the current treatment landscape for patients with MYC-dependent solid tumors, provide an overview of KB-0742 and further discuss the poster to be presented at the AACR-NCI-EORTC Interna
Company to discontinue Phase 3 entospletinib trial for strategic reasons Enrollment continues for Phase 1/2b trial in relapsed/refractory AML with Kronos Bio's next generation SYK inhibitor, lanraplenib Company on track to provide KB-0742 update from ongoing Phase 1/2 clinical trial in Q4 With $270.3 million in cash, cash equivalents and investments as of Sept. 30, 2022, Kronos Bio extends expected cash runway from Q4 2024 into Q2 2025 Conference call and webcast scheduled for today at 4:30 p.m. ET SAN MATEO, Calif. and CAMBRIDGE, Mass., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (NASDAQ:KRON), a company dedicated to transforming the lives of those affected by cancer, today
— KB-0742 cleared 80mg four-days-on, three-days-off dosing schedule in dose escalation — — Company expects to provide an efficacy update on this expansion cohort in 1H 2025 —SAN MATEO, Calif. and CAMBRIDGE, Mass., July 23, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (NASDAQ:KRON), a company dedicated to developing small molecule therapeutics that address cancers and other diseases driven by deregulated transcription, today announced the first patient dosed in an expansion cohort with KB-0742 at a dose of 80mg given on a four-days-on, three-days-off schedule. This expansion cohort is enrolling platinum-resistant patients with high-grade serous ovarian cancer (HGSOC), a tumor type which is part
Gainers Longeveron (NASDAQ:LGVN) stock increased by 74.6% to $3.16 during Thursday's regular session. The company's market cap stands at $20.0 million. BioRestorative Therapies (NASDAQ:BRTX) stock rose 27.4% to $1.72. The market value of their outstanding shares is at $11.6 million. Aethlon Medical (NASDAQ:AEMD) shares rose 26.84% to $0.66. The market value of their outstanding shares is at $3.3 million. Sharps Technology (NASDAQ:STSS) stock moved upwards by 23.58% to $0.37. The company's market cap stands at $6.5 million. Biomea Fusion (NASDAQ:BMEA) stock moved upwards by 20.95% to $5.6. The market value of their outstanding shares is at $201.2 million. iSpecimen (NASDAQ:ISPC) shares
The Dow Jones index closed lower by around 0.1% on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company’s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision. Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga’s insider transactions platform. Kronos Bio The Trade: Kronos Bio, Inc. (NASDAQ:KRON) President and CEO Norbert W Bischofberger bought a total of 3,005,122 shares at an average price of $1.04. To acquire these shares, it cost around $3.12 million. What's Happening: On May 21, Kro
SAN MATEO, Calif. and CAMBRIDGE, Mass., May 21, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (NASDAQ:KRON), a company dedicated to developing small molecule therapeutics that address cancers and other diseases driven by deregulated transcription, today announced that it has appointed Deborah Knobelman, Ph.D., as Chief Operating Officer and Chief Financial Officer effective June 3, 2024. Dr. Knobelman will oversee the finance, accounting, business development, investor relations and corporate strategy functions. "I'm excited to have Deb join our team. She is a proven life sciences leader, and her strategic vision will play a critical role in shaping the future of Kronos Bio. As we continue to
STOCKHOLM, SWEDEN / ACCESSWIRE / May 14, 2024 / Vicore Pharma Holding (STO:VICO) Stockholm, May 14, 2024 - Vicore Pharma Holding AB, a clinical-stage biopharmaceutical company unlocking the potential of a new class of drug candidates, angiotensin II type 2 receptor agonists (ATRAGs), is pleased to announce the election of Hans Schikan, PharmD, as the new Chair of the Board of Directors as well as the election of two new Board members, Ann Barbier, MD, PhD and Yasir Al-Wakeel BM, BCh.Hans Schikan has been a member of the Board since 2018 and is a leader in rare disease drug development and strategy. He was previously CEO of Prosensa (NASDAQ:RNA), a company developing therapies for rare diseas
Data from the Phase 1 dose escalation portion of the Phase 1/2 KB-0742 study will be presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in October 2023 The Company recently opened the third dosing cohort in the escalation portion of the Phase 1b/2 study of lanraplenib in combination with gilteritinib FLT3-mutated relapsed/refractory acute myeloid leukemia $219.7 million in cash, cash equivalents and investments as of June 30, 2023, providing expected cash runway into 2H 2025 SAN MATEO, Calif. and CAMBRIDGE, Mass., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (NASDAQ:KRON), a company dedicated to transforming the lives of those aff